LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

开始日期2025-09-01

申办/合作机构

Duke University

[+4]

ChiCTR2400094386

/ Suspended临床4期IIT

Clinical study of amphotericin B nebulized inhalation in the prevention of invasive fungal infections of the lungs in artificial liver therapy

开始日期2025-01-01

申办/合作机构-

NCT05865743

/ Recruiting临床3期IIT

PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients with Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)

The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia

开始日期2024-10-21

申办/合作机构

Radboud University Medical Center

[+2]

100 项与两性霉素B 相关的临床结果

登录后查看更多信息

100 项与两性霉素B 相关的转化医学

登录后查看更多信息

100 项与两性霉素B 相关的专利（医药）

登录后查看更多信息

26,506

项与两性霉素B 相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare

Article

作者: Bernauer, Mark ; Roth, Joshua A. ; Dorman, Stephanie ; Kratochvil, David

BACKGROUND:

Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.

METHODS:

We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd. The target patient population receiving annual first-line systemic therapy was calculated using Medicare enrollment data, SEER cancer incidence rates in patients age ≥65, and an assumption that 39.3% and 77.2% of new diagnoses receive systemic therapy for mCRC and mNSCLC respectively based on recent evidence. 76.0% of systemically treated mCRC patients and 11.4% of incident mNSCLC patients were expected to be treated with bevacizumab-based regimens based on recent evidence. Costs were derived from the 2024 Average Sales Price (ASP). Results include per-patient per-month (PPPM) cost savings (vs. originator), total monthly savings in the cohort, and number needed to convert (NNC) to biosimilar to fund the treatment of an additional 100 patients.

RESULTS:

PPPM savings from conversion to bevacizumab-bvzr were $4,205 in mCRC and $8,410 in mNSCLC. In 100% conversion scenarios, full cohort monthly savings were $27,664,432 in mCRC (n = 6,579) and $32,319,323 in mNSCLC (n = 3,843), respectively. At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr + FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr + paclitaxel + carboplatin. In mCRC and mNSCLC the biosimilar NNC from the originator was 47 and 43, respectively. The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.

CONCLUSION:

In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.

2025-12-31·Emerging Microbes & Infections

Chronic cutaneous and mucosal mucormycosis: Rhizopus arrhizus as a major pathogenic fungus

Article

作者: Yu, Jinlei ; Guo, Yanyang ; Li, Xingyu ; Miao, Chang ; Zhu, Zhenlai ; Liu, Fang ; Fu, Meng ; Yan, Dong ; Hai, Luming ; Ma, Yubo ; Gao, Jixin ; Wang, Gang

Chronic cutaneous mucormycosis is a rare condition distinct from the acute form, characterized by a prolonged, indolent course and varied clinical presentations. This study presents a 5-year experience from a tertiary dermato-mycology clinic, identifying six cases, the majority of whom were immunocompetent, with trauma history reported in four patients. The median duration from symptom onset to diagnosis was 60 months. The primary pathogens identified were Rhizopus arrhizus, Mucor variabilis, and Lichtheimia ramosa. Histopathological analysis demonstrated the absence of fungal angioinvasion, a hallmark of acute mucormycosis, which likely accounts for the slower progression observed in chronic cases. Systemic Amphotericin B treatment achieved favourable outcomes in most patients though significant morbidity persisted in some cases. This case series underscores the clinical and pathological distinctions of chronic cutaneous mucormycosis, highlighting the potential influence of host factors and environmental conditions on chronicity. The predominance of Rhizopus arrhizus suggests that chronicity is driven more by hostpathogen interactions than fungal species-specific factors. Increased recognition of the atypical clinical features, such as diverse cutaneous manifestation and slower progression course, as well as the utilization of diagnostic tools including histopathology, fungal culture, and advanced molecular techniques, is essential for the timely diagnosis of this rare presentation.

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity

Review

作者: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; Liu, Cong ; An, Yunfei ; He, Wuyang ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong

BACKGROUND:

Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.

OBJECTIVE:

We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.

METHODS:

A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.

RESULTS:

Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.

CONCLUSIONS:

The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.

190

项与两性霉素B 相关的新闻（医药）

2025-05-08

·吉利德科学

脂质体的多重角色：跨越生活与医药的边界

生活中，你或许留意过一些面霜的广告词，声称采用“脂质体包裹技术，深层渗透” [1]，又或许在选购鱼油时，看到过“脂质体鱼油，吸收率提升”的宣传[2]。脂质体的应用非常广泛，除了日常生活中的化妆品和食品领域，其在医药领域也发挥了极其重要的作用，例如抗真菌药物两性霉素B脂质体，就借助了脂质体技术优化了疗效，提升了安全性，成为临床上“狙击侵袭性真菌病”的有力武器。今天，我们就来揭秘脂质体这位“跨界明星”如何在抗真菌领域大放异彩。从生活到药物：脂质体的多方应用脂质体（liposome）是一种由磷脂等类脂形成的双分子层完全封闭的多层囊泡，能同时包裹水溶性成分和脂溶性成分两种物质，并且具有靶向高效、缓释可控和安全无毒的特点[3]。简而言之，脂质体就是像一辆一辆“微型运输车”，将有效成分运输到人体需要的地方。医学中使用的脂质体更是经过全方位升级，科学家利用磷脂双分子层构建出“细胞膜泡泡”，将强效药物镶嵌其中，并添加一个由聚乙二醇（PEG）组成的 “隐形涂层”，避免免疫系统的攻击。可以想象成，强效药物被这样装在脂质体的“小泡泡”里，让药物更安全、更精准地到达需要的地方。这种结构设计带来了三大革新性优势：毒性大幅降低，药物稳定性提高，还能突破血脑屏障等传统药物难以逾越的生理防线[1]。两性霉素B脂质体：可靠的抗真菌“猎手”作为自然界广泛存在的微生物，真菌既是生态环境的重要组成部分，也可能成为威胁人类健康的潜在病原体，甚至导致侵袭性真菌病（IFD）的发生，危及生命安全。数据显示，全球每年有超过655万人受到IFD的影响，导致超过375万人死亡，IFD是其中约255万人的直接死因。[4]重症监护病房（ICU）患者、接受过造血干细胞移植或血液恶性肿瘤患者、新生儿等都是IFD的高危人群[5]。两性霉素B的问世，让许多难治性IFD患者看到了希望。作为“抗真菌治疗金标准”[6]，两性霉素B抗真菌谱广、耐药罕见，但传统制剂由于其毒副作用大，难以足剂量使用，影响了治疗效果[7]。两性霉素B的脂质体结构[6]随着医学技术的进步，科研人员在针对两性霉素B的持续研发中，创造性地应用了脂质体载体技术，成功开发出两性霉素B脂质体（L-AmB）这一全新剂型。L-AmB不仅延续了传统制剂广谱强效的抗真菌实力，还通过靶向递送机制降低了毒副作用，提高了用药安全性，为危重患者提供了可靠的治疗选择[3]。不论是梳妆台上的护肤品，还是重症治疗药物的载体，脂质体技术既服务于日常护理，也守护着生命健康。科学的探索不会止步。在吉利德，科学家们不懈创新，突破不可能，从药物分子结构优化到生产工艺革新的每一个环节，都致力于为患者提供更安全、高效的治疗方案，点亮更多健康的希望。参考文献：[1] 代旭栋, 李云, 李双双, 李明媛, 张慧. 皮肤外用脂质体的研究进展[J]. 国际药学研究杂志, 2020, 47(11): 914-921.[2] Moloughney S. Liposomal delivery: The future for dietary supplement innovation[J]. Nutraceuticals World, 2023-10-18.[3] 冯赫宣, 李佩珊, 刘懿萱, 等. 脂质体的研究与应用进展[J]. 药学进展, 2024, 48(10): 725.[4] Denning, David W. Global incidence and mortality of severe fungal disease. The Lancet Infectious Diseases, Volume 24, Issue 7, e428-e438. doi: 10.1016/S1473-3099(23)00692-8.[5] 世界华人医学真菌专业委员会. 侵袭性肺真菌病诊断路径专家共识(2024版)[J]. 中华医学杂志, 2025, 105(16): 1-10. DOI: 10.3760/cma.j.cn114452-20240911-00506. [6] Cavassin, F. B., Queiroz-Telles, F., Bau´-Carneiro, J. L., & Vilas-Boas, R. R. (2021). Sixty years of Amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections. Infectious Diseases and Therapy, 10(1), 115–147. https://doi-org.libproxy1.nus.edu.sg/10.1007/s40121-020-00382-7[7] 孔旭东,王晓星,陈玥, 等. 两性霉素B不同制剂的药学特性和临床应用 [J]. 临床药物治疗杂志, 2022,20(7):7-12.关于吉利德科学吉利德科学是一家生物制药公司，成立三十多年来，探索并实现了多个医学上曾认为不可能实现的突破，旨在为公众创造一个更健康的世界。公司致力于推动药物革新，以预防和治疗HIV、病毒性肝炎、癌症和炎性疾病等可能威胁生命的疾病。吉利德在全世界超过35个国家和地区运营，总部位于美国加利福尼亚州福斯特市。2017年，吉利德正式开始在中国的商业运营，从病毒性肝炎、HIV防治，到抗真菌感染和肿瘤领域，我们承诺为国内的重疾患者提供创新的治疗手段及方案，助力实现“健康中国”的宏伟目标。短短几年，已有十三个吉利德全球领先的药物在中国获批，其中八个药物已被列入国家医保目录，让更多患者接受创新药物治疗、重回健康生活成为可能。与此同时，吉利德还在中国大力推动研发团队和能力的建设，以期实现更多三期临床在中国的同步开展，帮助加速创新疗法的审批，以更早惠及更多有需要的患者。

并购临床研究微生物疗法

2025-04-22

·爱尔真 Aerogen

【文献速递】肺移植术后雾化治疗的应用与临床获益

引言肺移植术后雾化治疗的临床意义肺移植是针对终末期肺部疾病患者的重要治疗手段，旨在延长生命并改善生活质量。然而，肺移植术后仍然面临着诸多挑战，包括急性排斥反应、慢性排斥反应以及感染等并发症，这些问题严重影响着患者的长期生存和移植肺的功能维持1。慢性肺同种异体移植功能障碍（CLAD），特别是其中的闭塞性细支气管炎综合征（BOS），是导致移植失败和患者死亡的主要原因之一2。因此，寻找有效预防和治疗这些并发症的方法至关重要。雾化治疗对于肺移植患者的意义雾化治疗作为一种将液体药物转化为细小雾滴，使其能够直接被患者吸入肺部的给药方式，在呼吸系统疾病的管理中占据着独特的地位3。与全身给药方式相比，雾化治疗具有提高局部药物浓度、减少全身暴露和潜在副作用的优势3。鉴于移植肺直接暴露于外部环境的特殊性，雾化治疗在肺移植患者中具有广阔的应用前景，有望在预防和治疗多种术后并发症方面发挥关键作用，从而改善患者的整体预后4。本报告旨在通过系统回顾中英文资料，深入探讨雾化治疗在肺移植患者中的应用、已证实的临床获益以及潜在的风险，以期为临床实践和未来的研究方向提供有价值的参考。肺移植的成功在很大程度上受到术后并发症的影响。雾化治疗通过靶向给药，有可能显著改善患者的治疗效果。移植肺与环境的直接接触使其更容易受到侵害，而雾化治疗恰好能将药物直接输送到这一关键部位。雾化治疗在肺移植术后感染管理中的应用与临床获益肺移植患者由于需要长期接受免疫抑制治疗以防止排斥反应，其免疫系统功能受到抑制，因此成为感染的高风险人群5。常见的感染类型包括细菌性肺炎和真菌感染，这些感染是导致患者发病率和死亡率增加的重要原因。1雾化抗生素在预防和治疗细菌感染中的应用：在肺移植患者中，雾化抗生素已被用于预防和治疗多种细菌感染，尤其针对那些对抗生素具有耐药性的菌株6。妥布霉素和黏菌素是临床实践中常用的雾化抗生素，它们对铜绿假单胞菌等难治性革兰阴性菌感染具有较好的抗菌活性6。此外，一些研究也探索了雾化阿米卡星和阿奇霉素在肺移植患者中的应用7。雾化抗生素的主要优势在于能够直接在肺部达到较高的药物浓度，从而提高局部杀菌效果，同时显著减少药物的全身暴露，降低潜在的肾毒性或耳毒性等全身副作用3。研究显示，雾化妥布霉素可用于预防供体肺部可能携带的感染，并且在肺移植患者入住重症监护室（ICU）期间，雾化抗生素可作为二级预防措施，防止新的感染发生6。雾化黏菌素已被证明可以有效地维持肺移植患者下呼吸道的无菌状态，降低患者的住院率，并可能对患者的长期生存产生积极影响8。然而，值得注意的是，雾化妥布霉素在部分患者中可能发生全身吸收，尤其是在需要机械通气的患者中，这可能导致血清药物浓度升高，并增加发生急性肾损伤的风险6。因此，对于接受雾化抗生素治疗的肺移植患者，特别是危重患者，需要密切监测药物的全身吸收情况和肾功能变化。2雾化抗真菌药物在预防和治疗真菌感染中的应用：真菌感染是肺移植患者面临的另一主要威胁。雾化抗真菌药物，特别是两性霉素B，已广泛应用于肺移植术后的真菌预防和治疗，尤其针对侵袭性真菌感染，如曲霉菌感染9。研究表明，雾化两性霉素B能够直接作用于肺部，最大限度地减少全身吸收和相关的毒性，因此被广泛用于肺移植术后的真菌预防，并且与极低的肺部真菌感染发生率相关10。此外，脂质体两性霉素B与传统的去氧胆酸盐两性霉素B相比，通常具有更好的患者耐受性10。一些研究还发现，延长雾化两性霉素B的疗程（超过3个月）可能比短期或中期的预防性治疗更能有效地预防侵袭性真菌感染，且不良反应的发生率没有显著增加11。除了两性霉素B，也有案例报道使用雾化伏立康唑、米卡芬净、利奈唑胺和万古霉素成功治疗肺移植患者的真菌感染12。特别地，雾化米卡芬净在治疗肺移植受者由念珠菌或微孢子菌引起的气管支气管炎方面显示出良好的安全性和有效性13。虽然雾化抗真菌药物通常具有良好的耐受性，但仍需密切关注患者可能出现的呼吸道症状，如咳嗽和支气管痉挛14。雾化治疗在改善肺移植患者气道分泌物清除方面的作用与临床获益肺移植术后，患者的气道分泌物清除能力常常受到影响15。这主要是因为移植的肺组织失去了原有的神经支配，导致纤毛清除功能减弱，咳嗽反射也可能受到抑制，从而使得气道内的分泌物容易潴留，增加了感染的风险。1雾化黏液溶解剂的应用：为了帮助肺移植患者清除气道内的黏液，临床上会使用雾化黏液溶解剂。常用的雾化黏液溶解剂包括N-乙酰半胱氨酸、高渗盐水和重组人脱氧核糖核酸酶（dornase alfa）16。高渗盐水通过增加气道黏膜表面液体层的容量，改变黏液的流变学特性，加速纤毛的清除功能，并刺激患者咳嗽，从而有助于清除气道内的分泌物15。Dornase alfa是一种重组人脱氧核糖核酸酶，它通过消化炎症细胞释放的细胞外DNA发挥作用，降低痰液的黏稠度，从而促进痰液的排出。在囊性纤维化患者中，dornase alfa已被证明具有长期改善肺功能的积极作用15。然而，一项针对肺移植术后下呼吸道感染患者的研究发现，雾化dornase alfa与雾化等渗盐水相比，在改善肺清除指数（LCI）方面没有显著差异17。目前，关于雾化黏液溶解剂在肺移植患者中的确切疗效，仍然缺乏充分的来自随机对照试验的证据42。尽管如此，在其他以黏液分泌过多为特征的呼吸系统疾病中，如囊性纤维化和支气管扩张症，雾化黏液溶解剂已显示出一定的益处18。雾化治疗在管理肺移植患者气道炎症和支气管痉挛方面的应用与临床获益雾化治疗在管理肺移植患者气道炎症和支气管痉挛方面的应用与临床获益。1雾化支气管扩张剂的应用：雾化支气管扩张剂，如沙丁胺醇和异丙托溴铵等短效β受体激动剂和抗胆碱能药物，常被用于缓解肺移植患者的支气管痉挛，改善气流受限19。这些药物通过直接作用于气道平滑肌，能够快速扩张支气管，缓解患者的呼吸困难症状，并改善肺功能指标20。研究表明，在肺移植术后早期使用雾化β2受体激动剂和抗胆碱能药物，可以加速肺部血管外水分的清除，有助于减轻肺水肿21。然而，一项针对脑死亡供体的研究显示，高剂量雾化沙丁胺醇并未能改善供体的氧合状态或增加可用于移植的肺的数量，反而更可能导致供体出现心动过速22。这提示在肺移植的不同阶段和不同人群中，雾化支气管扩张剂的应用可能需要更细致的评估。2雾化皮质类固醇的应用：吸入性皮质类固醇（ICS），如布地奈德和氟替卡松，已被研究用于管理肺移植患者的气道炎症23。一项研究表明，雾化布地奈德可能作为全身免疫抑制剂的辅助治疗，有助于控制肺移植术后患者的气道炎症，特别是淋巴细胞性细支气管炎24。然而，另一项研究发现，雾化氟替卡松丙酸酯在预防肺移植术后常见的慢性并发症——支气管闭塞综合征（BOS）方面效果不佳25。值得注意的是，在早期急性肺损伤或急性呼吸窘迫综合征（ARDS）患者中，雾化布地奈德显示出改善氧合和降低气道压力的作用，并能显著降低炎症标志物的水平26。此外，临床医生在使用雾化皮质类固醇时需要警惕潜在的药物相互作用。例如，雾化皮质类固醇可能与伊曲康唑等强效CYP3A4抑制剂发生相互作用，导致全身性皮质类固醇水平升高，从而引起库欣综合征等不良反应27。雾化治疗对肺移植患者肺功能、生活质量和生存率的总体临床获益评估雾化治疗在改善肺移植患者的整体临床结局方面显示出潜在的益处。研究表明，雾化治疗，特别是雾化免疫抑制剂如环孢素，在改善肺移植患者的生存率和无慢性排斥反应生存率方面具有显著的潜力4。一项重要的研究发现，对于出现早期器官排斥迹象的肺移植患者，吸入脂质体环孢素可以显著提高他们的生存几率并改善肺功能4。此外，雾化抗生素如黏菌素已被证明可以改善因囊性纤维化而接受肺移植的患者的长期生存率8。除了对生存率的潜在影响，雾化治疗在改善患者的生活质量方面也可能发挥积极作用28。这可能通过多种机制实现，例如改善患者的呼吸功能，减轻呼吸困难等症状，以及通过预防和治疗感染来减少疾病负担。肺康复计划，通常包括呼吸功能训练等环节，已被广泛认可为促进肺移植患者术后恢复、提高生活质量和改善生存结局的有效措施29。雾化治疗可以作为肺康复计划的一部分，进一步增强其效果。表1：雾化治疗对肺移植患者临床结局的潜在影响总结雾化治疗在肺移植排斥反应管理中的应用肺移植后，患者的免疫系统可能将移植的肺部识别为外来物质并对其发起攻击，导致排斥反应。排斥反应是影响移植肺功能和患者长期生存的主要障碍，包括急性排斥反应和慢性排斥反应，其中慢性排斥反应最常见的是闭塞性细支气管炎综合征（BOS）1。1雾化免疫抑制剂的应用探索：为了直接针对移植肺部的免疫反应，研究人员一直在探索雾化免疫抑制剂在肺移植排斥反应管理中的应用。雾化环孢素：研究表明，通过雾化方式给予环孢素可以直接在肺组织中达到比全身给药更高的药物浓度，从而更有效地预防和治疗排斥反应，同时显著降低全身副作用19。临床试验结果显示，雾化环孢素与传统的全身免疫抑制治疗联合使用，可以显著降低慢性排斥反应的发生率，提高患者的生存率，并且观察到的副作用通常较为轻微，主要包括气道刺激和支气管痉挛19。更进一步的研究表明，雾化脂质体环孢素在改善已经发生BOS的肺移植患者的生存率和肺功能方面也显示出积极的效果4。雾化他克莫司：除了环孢素，研究人员也开始探索其他雾化免疫抑制剂的应用。一项案例报告描述了雾化他克莫司在治疗一名患有BOS的肺移植受者中取得了临床改善，患者的功能能力和氧合状态均有所提高30。初步研究表明，雾化他克莫司在肺移植患者中具有可行性和安全性，并且能够达到可预测的药物浓度31。这为未来进一步研究雾化他克莫司在肺移植排斥反应管理中的作用奠定了基础。雾化治疗在肺移植患者中的潜在风险或副作用尽管雾化治疗在肺移植患者中具有诸多潜在的益处，但也存在一些潜在的风险和副作用需要临床医生和患者关注23。这些风险既包括药物本身可能引起的副作用，也包括雾化设备使用不当可能导致的问题。例如，雾化抗生素如妥布霉素可能引起患者出现耳鸣、发音困难、支气管痉挛和听力损失等不良反应，并且存在导致肾毒性的潜在风险7。雾化黏菌素则可能引起咳嗽、支气管痉挛和咽喉刺激等不适症状7。雾化抗真菌药物，如常用的两性霉素B，可能会导致患者出现呼吸急促、咳嗽、味觉异常和支气管痉挛等副作用7。对于雾化免疫抑制剂，如环孢素，一些患者可能会出现气道刺激和支气管痉挛等反应19。在早期的研究中，使用粉末制剂的雾化环孢素曾报告引起持续性咳嗽和咽喉疼痛等副作用，这提示药物制剂的选择和雾化设备的优化对于减少不良反应至关重要4。此外，雾化治疗的有效性受到多种因素的影响，包括所使用的雾化器的类型、药物的剂量、患者的吸入技术以及患者肺部的病理生理状态等32。如果不规范地使用雾化设备或药物，可能导致药物无法有效地输送到肺部，从而影响治疗效果，甚至可能对患者造成潜在的危害32。因此，对患者进行充分的教育和培训，确保他们掌握正确的雾化吸入技术，对于提高治疗效果和减少不良反应至关重要。爱尔真技术在肺移植术后雾化治疗的应用爱尔真作为全球急重症领域雾化解决方案领导者，通过Aerogen Solo加Aerogen Ultra的组合，能为患者提供高达34%的雾化药物肺部沉积率。同时，爱尔真与其他外部合作伙伴（如两性霉素B及多粘菌素的生产厂家），结合多方产品优势，积极在肺移植术后治疗领域开展合作和探索，已在国内外多家医院开展使用爱尔真产品的治疗及康复管理，为患者提供院内及院外的全流程雾化治疗解决方案。结论与未来展望综上所述，雾化治疗在肺移植患者的术后管理中展现出广泛的应用前景和显著的临床获益。它不仅在预防和治疗感染方面发挥着关键作用，通过雾化抗生素和抗真菌药物直接作用于肺部，提高了局部药物浓度，降低了全身毒性；同时，雾化支气管扩张剂和皮质类固醇在管理气道炎症和支气管痉挛方面也显示出一定的疗效。更重要的是，雾化免疫抑制剂如环孢素的出现，为预防和治疗慢性排斥反应（BOS）带来了新的希望，并可能改善患者的长期生存率和生活质量。虽然雾化黏液溶解剂在肺移植患者中的作用仍需进一步研究证实，但其在改善气道分泌物清除方面也具有潜在价值。未来的研究方向应侧重于进一步优化雾化药物的种类、剂量、给药方案和递送设备，以提高治疗效果并减少副作用。同时，需要进行更大规模、设计严谨的随机对照试验，以更充分地评估雾化治疗在肺移植患者中的长期临床获益和安全性。此外，探索雾化治疗与其他治疗方法（如肺康复、全身免疫抑制剂调整）的协同作用，有望为肺移植患者提供更全面、更有效的治疗策略，从而实现更好的长期预后。引用文献目录：[1]Life after lung transplant - Pulmonary Fibrosis Foundation, https://www.pulmonaryfibrosis.org/docs/default-source/programs/educational-materials/life-after-lung-transplant/post-transplant-booklet.pdf[2]Lung Transplant - Renovion, https://www.renovion.com/lung-transplant[3]Aerosolized Administration of Drugs: Possible Future Agents and the Role of the RCP, https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/asthma/aerosolized-administration-of-drugs-possible-future-agents-and-the-role-of-the-rcp/[4]Inhaled immunosuppressant could improve prognosis of lung transplant patients, https://www.news-medical.net/news/20191113/Inhaled-immunosuppressant-could-improve-prognosis-of-lung-transplant-patients.aspx[5]Bacterial infections in lung transplantation - McCort - Journal of Thoracic Disease, https://jtd.amegroups.org/article/view/51507/html[6]Tobramycin Systemic Absorption in Lung Transplant Recipients Treated With Inhaled Tobramycin: A Cohort Study - Frontiers Publishing Partnerships, https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12579/full[7]Inhaled Antibiotics for Lower Airway Infections - PMC, https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC4028738/[8]Inhaled colistin following lung transplantation in colonised cystic fibrosis patients, https://publications-ersnet-org.libproxy1.nus.edu.sg/content/erj/42/2/542[9]Nebulized Amphotericin B Dosing Regimen for Aspergillus Prevention After Lung Transplant, https://www.ectrx.org/class/pdfPreview.php?year=2021&volume=19&issue=1&supplement=0&spage_number=58&makale_no=0[10]Design of Aerosolized Amphotericin B Formulations for Prophylaxis Trials among Lung Transplant Recipients - Oxford Academic, https://academic-oup-com.libproxy1.nus.edu.sg/cid/article/39/Supplement_4/S207/321410[11]Efficacy of different durations of antifungal prophylaxis with nebulized amphotericin B after lung transplantation: a retrospective cohort study, https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC10636437/[12]New nebulized treatment options for bronchial infection in lung transplant, https://publications-ersnet-org.libproxy1.nus.edu.sg/content/erj/56/suppl64/1940[13]Nebulized Micafungin Treatment for Scopulariopsis/Microascus Tracheobronchitis in Lung Transplant Recipients | Antimicrobial Agents and Chemotherapy - ASM Journals - American Society for Microbiology, https://journals-asm-org.libproxy1.nus.edu.sg/doi/10.1128/AAC.02174-20[14]Nebulized Amphotericin B Dosing Regimen for Aspergillus Prevention After Lung, Transplant https://www.ectrx.org/detail/current/2021/19/1/0/58/0[15]Investigating the role of nebulised mucolytic therapy during lower respiratory tract infections post lung transplantation - ClinicalTrials.gov, https://cdn.clinicaltrials.gov/large-docs/70/NCT01952470/Prot_SAP_000.pdf[16]Oral Inhaled Medications-Beyond Bronchodilators - U.S. Pharmacist, https://www.uspharmacist.com/article/oral-inhaled-medications-beyond-bronchodilators[17]Dornase alfa during lower respiratory tract infection post lung transplantation: a randomized controlled trial | Request PDF - ResearchGate, https://www.researchgate.net/publication/330315622_Dornase_alfa_during_lower_respiratory_tract_infection_post_lung_transplantation_a_randomized_controlled_trial[18]Timing of dornase alfa inhalation for cystic fibrosis - Dentice, R - 2021 | Cochrane Library,https://www-cochranelibrary-com.libproxy1.nus.edu.sg/cdsr/doi/10.1002/14651858.CD007923.pub6/abstract[19]Helping Lung Transplantees to Successful Outcomes » Aerosolized Cyclosporine,https://secondwindstl.org/who-we-are/articles-by-dr-hacheem/aerosolized-cyclosporine/[20]Critical Care Management of Severe Asthma Exacerbations - MDPI, https://www.mdpi.com/2077-0383/13/3/859[21]Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury - Tech Science Press, https://www.techscience.com/biocell/v45n5/43077/html[22]A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors - PubMed, https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/24730050/[23]Immunosuppression in lung transplantation - PMC, https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC4133546/[24]Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation - PubMed, https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/11673211/[25]Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial - PubMed, https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/12085003/[26]Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study - PMC, https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC5292862/[27]Addition of inhaled fluticasone propionate to systemic immunosuppression after lung transplantation: Cushing's syndrome in patients on itraconazole comedication | Request PDF - ResearchGate, https://www.researchgate.net/publication/10657707_Addition_of_inhaled_fluticasone_propionate_to_systemic_immunosuppression_after_lung_transplantation_Cushing's_syndrome_in_patients_on_itraconazole_comedication[28]Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness, https://publications-ersnet-org.libproxy1.nus.edu.sg/content/erj/24/4/674[29]The efficacy of pulmonary rehabilitation training program for patients after lung transplantation - Journal of Thoracic Disease, https://jtd.amegroups.org/article/view/82564/html[30]Aerosolized tacrolimus: a case report in a lung transplant recipient - PubMed, https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/21094875/[31]Full article: Inhaled immunosuppressants after lung transplantation –real potential to enhance patient outcomes, https://www-tandfonline-com.libproxy1.nus.edu.sg/doi/full/10.1080/17476348.2024.2434152?src=exp-la[32]European Respiratory Society Guidelines on the use of nebulizers, https://publications-ersnet-org.libproxy1.nus.edu.sg/content/erj/18/1/228

临床研究

2025-04-21

·GlobeNewswire-Health Care

Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025

April 16, 2025, Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today scientific presentations on Basilea’s clinical-stage novel antifungal fosmanogepix given at ESCMID Global 2025, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 11 to 15, 2025 in Vienna, Austria. Further presentations covered the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®). Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “Invasive fungal infections are an increasing global health problem and novel antifungals are urgently needed. To date more than 250 patients suffering from difficult-to-treat invasive fungal infections have received fosmanogepix via expanded access. The data presented at ESCMID highlight the potential of fosmanogepix as a life-saving treatment option in severe fungal infections, based on the results from a large cohort of patients with invasive fusariosis, as well as from patients with mucormycosis, who received fosmanogepix via expanded access. We look forward to the start of our second phase 3 study with fosmanogepix covering a broad range of mold infections, including aspergillosis, fusariosis and mucormycosis.” More than 250 patients from 11 countries with serious or life-threatening invasive fungal infections, who progressed on antifungal standard-of-care treatment, experienced treatment-limiting toxicities, or had infections with resistant fungal pathogens, received fosmanogepix via expanded access to date (NCT06433128). As presented at ESCMID, treatment with fosmanogepix resulted in favorable response rates of 70% or higher in patients with invasive fusariosis or mucormycosis and it was tolerated for long treatment durations. Further presentations reported on the activity of fosmanogepix against diverse yeast and mold species collected as part of a worldwide surveillance program. — Presentation IPT13: Fosmanogepix – a novel clinical phase 3 stage antifungal agent – M. Engelhardt — Presentation O0419: Fosmanogepix expanded access in patients withFusariuminfections – S. Dadwal, A. Baluch, J. Dickter, J. R. Newman, M. H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner — Poster P4164: Fosmanogepix expanded access case series in patients with mucormycosis – A. Puing, A. Kaur, Y. J. Lee, P.Chang, A. Koff, D. Tyungu, M. Oldham, M. Shaughnessy, A. Tande, H. Schlamm, J. Maertens — Poster E0237:Activity of manogepix against a worldwide collection of mould isolates from 2023–M. Winkler, S. Edeker, A. Klauer, P. R. Rhomberg, M. Castanheira — Poster P2891:Activity of manogepix against a worldwide collection of yeast isolates from 2023–M. Winkler, S. Edeker, A. Klauer, P. R. Rhomberg, M. Castanheira — Poster P2944: Deciphering Connections between Isavuconazole (ISAV) Drug Exposures and Responses Among Different Infections: Mucorales – L. Kovanda, A. Desai — Poster P2945: Deciphering Connections Between Isavuconazole Drug Exposures and Responses Among Different Infections: Dimorphic Fungi/Mould/Other Filamentous Fungi and Mixed Infections – A. Desai, L. Kovanda — Poster P2946: Deciphering Connections Between Isavuconazole Drug Exposures and Responses Among Different Infections: Invasive Candidiasis – L. Kovanda, A. Desai — Poster E0050: Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration – A. Desai, L. Kovanda — Poster E0055: High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis – S. Wurster, N. D. Albert, N. P. Wiederhold, R. E. Lewis, D. P. Kontoyiannis Ceftobiprole (Zevtera) data presented at ESCMID Global 2025 — Poster E0792: Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant Enterococcus faecalis – O. Funk, I. Khan, J. Li, J. Cusumano Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the US Food and Drug Administration for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP). This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. In the 27 European Union member states, as well as in Iceland, Liechtenstein and Norway, isavuconazole is approved for patients aged from 1 year of age and older for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.3 Isavuconazole is also approved in the United States (US)4 and several additional countries in Europe and beyond, including the United Kingdom5, the Middle East and North Africa region, the Asia Pacific region, China and Japan.6 It has orphan drug designation in the US, Europe and Australia for its approved indications. Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.7 In several countries in Europe and beyond, the brand is currently approved and marketed as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP).7 In the United States, ZEVTERA® is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).8 Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC): ClinicalTrials.gov identifier: NCT05421858 European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: April 15, 2025] Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: April 15, 2025] Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: April 15, 2025] The registration status and approved indications may vary from country to country. Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: April 15, 2025] The content above comes from the network. if any infringement, please contact us to modify.

孤儿药临床结果上市批准快速通道

100 项与两性霉素B 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00203	两性霉素B	G01AA03 J02AA01 A01AB04	DB00681

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
利什曼病	日本	Sumitomo Pharma Co., Ltd.	2009-06-17
粒细胞减少性发热	日本	Sumitomo Pharma Co., Ltd.	2006-04-20
念珠菌病	日本	Fuji Pharma Co., Ltd.	1997-01-31
侵袭性真菌感染	日本	Clinigen KK	1963-04-18
真菌病	-	Bristol Myers Squibb Co.	1958-01-01
复杂的尿路感染	中国	-	-
细菌性心内膜炎	中国	-	-
脑膜炎	中国	-	-
脓毒症	中国	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
隐球菌脑膜炎	临床3期	-	Matinas BioPharma Nanotechnologies, Inc.	2023-01-01
肺部疾病	临床3期	美国	Enzon Pharmaceuticals, Inc.	2005-10-01
侵袭性念珠菌病	临床2期	-	石药集团中奇制药技术（天津）有限公司	2020-01-01
侵袭性曲霉菌病	临床2期	-	石药集团中奇制药技术（天津）有限公司	2020-01-01
急性髓性白血病	临床2期	-	Matinas BioPharma Nanotechnologies, Inc.	2019-08-01
前体B细胞急性淋巴细胞白血病	临床2期	-	Matinas BioPharma Nanotechnologies, Inc.	2019-08-01
外阴阴道念珠菌病	临床2期	美国	Matinas BioPharma Nanotechnologies, Inc.	2016-11-01
酵母菌感染	临床2期	美国	Matinas BioPharma Nanotechnologies, Inc.	2016-11-01
慢性皮肤黏膜念珠菌病	临床2期	美国	Matinas BioPharma Nanotechnologies, Inc.	2016-09-27
口腔念珠菌病	临床2期	美国	Bristol Myers Squibb Co.	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04059770 (CTgov)	临床2期	组织胞浆菌病 \| 获得性免疫缺陷综合征	118	single dose of L-AmB (Single Dose of L-AmB)	鬱蓋顧鏇鬱蓋獵廠糧築 = 遞選齋餘憲醖壓廠餘鑰觸繭簾遞壓憲衊憲壓襯 (簾蓋衊積繭積網襯廠醖, 簾膚選觸鑰築壓襯餘顧 ~ 鑰選膚願壓衊壓夢鏇鏇) 更多	-	2025-03-14
				2 doses of L-AmB (2 Doses of L-AmB)	鬱蓋顧鏇鬱蓋獵廠糧築 = 廠憲壓觸選築膚遞鑰鬱觸繭簾遞壓憲衊憲壓襯 (簾蓋衊積繭積網襯廠醖, 壓蓋願築齋獵獵艱衊糧 ~ 願襯衊遞淵築窪衊觸蓋) 更多
NCT06376201 (NEWS) 人工标引	临床4期	侵袭性真菌感染	55	两性霉素B胆固醇硫酸酯复合物	繭襯齋蓋鬱廠網蓋築範(鹹廠膚選醖艱鑰糧範鬱) = 鬱鏇齋簾築鬱鏇選膚鹹餘窪膚築鹹繭選願繭齋 (廠鹽窪糧廠窪鹹蓋構憲 ) 更多	积极	2025-03-11
SNMMI2024	N/A	-	-	Amphotericin B	鏇繭壓夢膚齋膚膚醖願(願淵鏇醖糧鏇築繭鏇艱) = 願齋範鏇鹹鹹鬱繭淵鬱蓋繭衊蓋範構鑰憲獵築 (築構鹹製鹹餘醖願壓淵 )	-	2024-06-09
EHA2024	N/A	血液肿瘤	21	Liposomal Amphotericin B (L-AMB) (Group A (poor response to other antifungal drugs))	廠艱選鬱觸簾鬱鹽鹹壓(簾憲選壓網齋獵鏇製獵) = 齋構製糧築範製觸鹹鹽蓋廠廠範鬱蓋廠構獵齋 (襯願廠衊壓築遞鑰襯製 )	积极	2024-05-14
				Liposomal Amphotericin B (L-AMB) (Group B (cannot tolerate adverse reactions))	廠艱選鬱觸簾鬱鹽鹹壓(簾憲選壓網齋獵鏇製獵) = 壓鹹壓鏇築獵選簾襯觸蓋廠廠範鬱蓋廠構獵齋 (襯願廠衊壓築遞鑰襯製 )
GlobeNewswire 人工标引	N/A	镰刀菌病	3	MAT2203	顧淵簾艱鑰範網獵襯齋(遞醖憲獵範獵製窪窪構) = 簾淵艱獵夢願膚鹽醖膚選窪獵願製製壓蓋構鏇 (鑰蓋憲襯鹹簾選獵壓廠 )	积极	2024-03-22
GlobeNewswire 人工标引	N/A	侵袭性真菌感染	19	MAT2203	繭糧網築糧鹹獵艱簾鏇(願範網艱選淵淵襯遞鹽) = 壓艱廠餘糧餘襯製襯糧遞憲廠憲網淵繭積鑰鏇 (艱蓋鬱範醖鹽積製廠膚 ) 更多	积极	2024-02-26
APAO2024	N/A	-	-	Optisol-GS with amphotericin B supplementation	鹹範遞簾顧積淵餘膚鹹(淵糧獵鏇窪憲艱餘遞構) = 衊繭鏇製繭餘獵簾襯夢鹽製淵醖鹹鹹範衊憲淵 (糧網製繭夢襯鏇鹹齋積 ) 更多	-	2024-02-22
				Optisol-GS without amphotericin B supplementation	鹹範遞簾顧積淵餘膚鹹(淵糧獵鏇窪憲艱餘遞構) = 遞範構艱鹽餘淵範淵襯鹽製淵醖鹹鹹範衊憲淵 (糧網製繭夢襯鏇鹹齋積 ) 更多
NCT04031833 (Pubmed \| Clin Infect Dis)	临床1/2期	隐球菌脑膜炎	80	Oral LNC Amphotericin B + Flucytosine	襯網簾衊鏇齋獵獵鏇鹹(艱製壓衊壓鹹鹽願積積) = 簾衊鹹簾獵襯遞鹽襯蓋鹹範醖餘範壓糧壓壓顧 (壓淵鏇鬱範餘窪鬱簾簾 ) 更多	-	2023-08-22
				IV Amphotericin + Flucytosine	襯網簾衊鏇齋獵獵鏇鹹(艱製壓衊壓鹹鹽願積積) = 築範窪襯襯鬱衊築廠簾鹹範醖餘範壓糧壓壓顧 (壓淵鏇鬱範餘窪鬱簾簾 ) 更多
WCD2023	N/A	皮肤利什曼病	28	Liposomal amphotericin B 12 mg/kg	醖選糧網遞願淵糧夢窪(鬱構選膚簾窪觸願鹽簾) = 積艱製鏇獵網繭範遞淵夢構製醖鹹顧顧鏇窪願 (廠觸餘鏇積製獵鑰獵鹹 ) 更多	积极	2023-07-06
				Liposomal amphotericin B 18 mg/kg	醖選糧網遞願淵糧夢窪(鬱構選膚簾窪觸願鹽簾) = 製齋壓醖壓壓繭鑰築壓夢構製醖鹹顧顧鏇窪願 (廠觸餘鏇積製獵鑰獵鹹 ) 更多
ISN WCN2023	N/A	毛霉菌病	-	Liposomal amphotericin (LAmB)	膚鏇衊鬱憲顧鏇願築鬱(糧憲艱廠選簾憲願齋齋) = 齋製繭餘鬱鑰壓餘齋簾製獵築衊餘餘襯鏇遞壓 (廠簾餘窪築壓築衊衊鹹 ) 更多	-	2023-03-01